The prolargin protein may serve as a biomarker for pulmonary arterial hypertension (PAH), allowing for earlier diagnosis and differentiating among different types of pulmonary hypertension (PH), according to a recent study. The study, “Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension,” was…
News
The National Organization for Rare Disorders (NORD) is seeking individuals willing to share real-life experiences with rare diseases to speak at its upcoming virtual Living Rare, Living Stronger NORD Patient and Family Forum. The interactive, patient-focused forum will be held online June 26-27. The deadline to apply for…
A gene called DNMT3B was found for the first time to be a mediator of blood vessel wall growth, and has been implicated in the development of pulmonary hypertension (PH) in a rat study. This gene, which regulates inflammatory pathways…
Elevated blood levels of the kidney disease biomarker creatinine and the heart failure biomarker NT-proBNP were found to be independent predictors of mortality for older people with pulmonary arterial hypertension (PAH) who were born with congenital heart disease…
United Therapeutics is planning to ask the U.S. Food and Drug Administration (FDA) for an accelerated review of Tyvaso DPI, an investigational therapy-inhaler device treatment for two forms of pulmonary hypertension, in an approval request it expects to file by midyear. The request, in the form of a new drug…
Throughout 2020, Pulmonary Hypertension News brought daily coverage of groundbreaking research, treatment advancements, and clinical trial developments related to pulmonary hypertension (PH). As we anticipate bringing you more PH news this year, we take a look back…
Occlutech’s atrial flow regulator (AFR) — a cardiac implant — received breakthrough device designation from the U.S. Food and Drug Administration for the treatment of pulmonary arterial hypertension (PAH). Breakthrough status is given to medical equipment that offer significant advantages over currently available options for the treatment of…
Researchers have designed a Phase 2 clinical trial to test the safety and preliminary effectiveness of Revatio (sildenafil) in preventing pulmonary hypertension (PH) in premature infants with severe bronchopulmonary dysplasia (BPD). An overview of the study, “Safety of sildenafil…
Matt J. Granato is the newly named president and CEO of the Pulmonary Hypertension Association (PHA), the nonprofit group announced. Granato, who has more than 20 years of experience working in nonprofits and healthcare associations, will assume this office and its duties on Jan. 4. He is the third…
The European Commission has granted orphan drug designation to sotatercept for the treatment of people with pulmonary arterial hypertension (PAH). This designation is given to medications with the potential to substantially improve care for rare diseases — defined as those that affect fewer than five individuals per 10,000…
Treatment with bosentan may lower the risk of developing pulmonary hypertension (PH) and help stabilize lung function in scleroderma patients with digital ulcers, a study suggests. Patients who never had taken bosentan had a 3.9 times increased risk for PH compared to those on this therapy, findings…
Lower quality of life in patients with pulmonary hypertension (PH) was found to be associated with higher burden experienced by their caregivers, according to a study conducted in Turkey. The study, “Caregiver Burden in Patients with Pulmonary Hypertension,” was published in the journal Clinical Nursing…
